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y. Abstract 
 Lipid peroxidation products like malondialdehyde, 4-hydroxynonenal and F 2 -isoprostanes are widely used as markers of 
oxidative stress  in vitro and  in vivo . This study reports the results of a multi-laboratory validation study by COST Action B35 
to assess inter-laboratory and intra-laboratory variation in the measurement of lipid peroxidation. Human plasma samples 
were exposed to UVA irradiation at different doses (0, 15 J, 20 J), encoded and shipped to 15 laboratories, where analyses of 
malondialdehyde, 4-hydroxynonenal and isoprostanes were conducted. The results demonstrate a low within-day-variation 
and a good correlation of results observed on two different days. However, high coeffi cients of variation were observed 
between the laboratories. Malondialdehyde determined by HPLC was found to be the most sensitive and reproducible lipid 
peroxidation product in plasma upon UVA treatment. It is concluded that measurement of malondialdehyde by HPLC has 
good analytical validity for inter-laboratory studies on lipid peroxidation in human EDTA-plasma samples, although it is 
acknowledged that this may not translate to biological validity. 
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y. Abbreviations: BHT ,  Butylated hydroxytoluene; BSA ,  Bovine serum albumin; BSTFA ,  bis-(trimethylsilyl) trifl uoroacetamide;
CV inter , Inter-laboratory coeffi cient of variation; CV intra ,  Intra-laboratory coeffi cient of variation; DNP ,  2,4-Dinitrophenyl-
hydrazone; DNPH ,  2,4-Dinitrophenylhydrazine; ELISA ,  Enzyme-linked immunosorbent assay; F2-IsoPs ,  F 2 -isoprostanes; 
GC-NICI-MS ,  Gas chromatography negative ion chemical ionization mass spectrometry; HNE ,  4-Hydroxy-trans-2-
nonenal; HPLC ,  High performance liquid chromatography; LC-MS ,  Liquid chromatography mass spectrometry; MDA , 
 Malondialdehyde; ODS ,  Octadecylsilane; PBS ,  Phosphate buffered saline; PUFA ,  Polyunsaturated fatty acid; RP ,  Reverse 
phase; TBA ,  Thiobarbituric acid; TBARS ,  Thiobarbituric acid reactive substances; TMB ,  3,3 ’ ,5,5 ’ -Tetramethylbenzidine; TPP , 
 Triphenylophosphine; UVA ,  Ultraviolet light A.  Introduction 
 Biological membranes and plasma lipoproteins all 
contain signifi cant proportions of polyunsaturated 
fatty acids (PUFAs), which make them susceptible 
to oxidative attack by free radicals and results in 
peroxidation of the fatty acyl chains. Following the 
generation of peroxyl radicals and hydroperoxides, 
rearrangement can lead to formation of relatively 
more stable long-chain oxidation products such as 
isoprostanes, which have prostaglandin-like struc-
tures but are not synthesized by cyclo-oxygenase [1]; 
the F2-isoprostane forms (F2-IsoPs) are the most 
abundant in plasma and urine. Alternatively, peroxyl 
radicals or endoperoxides may undergo cleavage to 
release short chain secondary products, often 
aldehydes, as in the examples of malondialdehyde 
(MDA), pentanal and 4-hydroxy-2-nonenal (HNE) 
[2]. Many lipid peroxidation products, both full chain 
and chain-shortened, have been reported to demon-
strate harmful or pro-infl ammatory effects [3 – 5]. 
There are many studies supporting the idea that oxi-
dative stress and specifi cally the oxidative degrada-
tion of PUFAs is involved in many pathological 
processes. Overwhelming evidence has accumulated 
over the last decade, indicating that oxidation of 
lipids plays an important role in the development 
of multiple acute and chronic human diseases like 
cancer, atherosclerosis and others [6 – 8]. While cell 
membrane lipid peroxidation may lead to loss of 
viability, altered signalling and tissue dysfunction, in 
plasma the oxidation of lipoproteins is probably 
a major contributor to the formation of lipid 
peroxi dation products and is widely thought to be 
involved in atherosclerosis. Malondialdehyde (MDA), 
4-hydroxy-2-nonenal (HNE) and F2-isoprostanes 
(F2-IsoPs) are now the most studied products of 
lipid peroxidation. MDA and HNE are aldehydes 
that react with a variety of biomolecules, such as pro-
teins, lipids and nucleic acids, and they are thought 
to contribute to the pathogenesis of human chronic 
diseases [6]. Furthermore, their relatively long half-
life makes them candidates for the propagation of 
damage to neighbouring cells . F2-IsoPs exert bio-
logical actions and may be pathophysiological medi-
ators of diseases [9,10]; their formation correlates 
with a variety of pathological syndromes associated 
with oxidative stress [11].  Quantifi cation of lipid peroxidation can be assessed 
by the detection of products of PUFA peroxidation. 
Several markers for lipid peroxidation  in vitro and  in 
vivo are available [12] and different methods for 
detection of lipid peroxidation in biological samples 
have been described for each marker by numerous 
authors [6,13,14]. Previously, the differences in sev-
eral markers of oxidative stress were investigated using 
a rodent model of oxidative damage (CCl 4 adminis-
tration) in the biomarker of oxidative stress study 
(BOSS), a multi-centre study in which samples were 
generated in one laboratory and distributed to other 
laboratories for analysis of each different marker [15]. 
This study identifi ed plasma MDA and plasma and 
urinary F2-IsoPs as promising candidates for free 
radical damage induced by CCl4, especially with 
analysis by GC/NICI-MS. On the other hand oxida-
tion products of plasma proteins (protein carbonyl, 
methionine sulphoxide and 3-nitrotyrosine) and leu-
kocyte DNA (comet assay) did not appear to be reli-
able oxidation markers in this model [15]. Other 
studies have reported, mainly with respect to analysis 
of DNA oxidation products, that methods of oxida-
tive stress detection often lack sensitivity and specifi c-
ity and might be disturbed by interference coming 
from related products or over-estimation resulting 
from the analysis conditions, i.e. artefacts [16 – 18]. It 
is likely that similar problems may affect markers of 
oxidative damage resulting from lipid peroxidation. 
In particular, the combination of parameter and 
method variety, together with unstable analytes, 
almost certainly contributes to the high variation seen 
in some published estimates of oxidative damage to 
biological lipids. Proudfoot et al. [19] have shown that 
there are wide limits of agreement between the mea-
surement of F2-IsoPs by an enzyme immunoassay 
and gas chromatography/mass spectrometry, with 
only 28% of the values within the 95% confi dence 
limits for the difference. The values for F2-IsoPs 
reported vary considerably depending on whether 
total (esterifi ed plus free) or free F2-IsoPs and one or 
several regioisomers are being measured; e.g. levels of 
3 – 25 pg/mL were observed with LC-(APCI)-MS/MS 
for free 8-iso-PGF2 α [20], whereas values in the 
range 200 – 300 pg/mL for total F2-IsoPs have been 
found by GC-NICI-MS [21 – 24]. Lykkesfeldt [25] 
compared malondialdehyde values obtained by 
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y.HPLC with fl uorescence detection and a direct 
spectrophotometric method and reported an over-
estimation by spectrophotometry; a similar fi nding 
had been reported previously for a comparison of 
MDA and TBARS analysis [26]. This discrepancy 
may be explained by the fact that HPLC with 
fl uorescence detection quantifi es only the genuine 
MDA-(TBA) 2 adduct, whereas the total absorbance 
of several thiobarbituric acid reactive substances 
(TBARS) is measured by the direct spectrophotomet-
ric method. In many TBA-dependent methods lipid 
hydroperoxides are also degraded to release MDA 
during the assay [1] and the measured levels can also 
be infl uenced by whether acidic hydrolysis is used to 
release protein-bound MDA. Furthermore, it is likely 
that the inconsistent results often found in the fi eld 
of oxidative stress intervention studies might be due 
to a lack of accuracy and comparability of the available 
methods for lipid peroxidation detection. It is very 
important to address this point, in order to under-
stand the implications on studies of oxidative stress 
where lipid peroxidation parameters are measured. 
 Although the research reported by the BOSS group 
provided important information on the potential of 
various assays of lipid peroxidation to detect free radical 
damage in a rodent model, there is still a lack of infor-
mation from studies addressing the inter-laboratory 
variability of particular lipid peroxidation assays. The 
present study was carried out to address this issue in 
human plasma and assess the inter-laboratory and 
intra-laboratory variation in the measurement of lipid 
peroxidation. Fifteen laboratories within the European 
COST Action B35 on  ‘ Lipid peroxidation associated 
disorders ’ undertook a multi-laboratory validation 
study using human plasma samples that were gener-
ated by a single laboratory and distributed to the par-
ticipating groups. The plasma was oxidized by exposure 
 ex vivo to ultraviolet A irradiation (UVA) at different 
doses and three separate markers of lipid peroxidation 
were measured by different methods. The specifi c aims 
of the study were to investigate the intra-laboratory 
variability with two different batches of fi ve identical 
samples; to compare analysis of the same lipid per-
oxidation product between different laboratories; to 
investigate which methods had the sensitivity to detect 
increased levels of lipid peroxidation expected with the 
two severities of treatment  ex vivo . 
 Materials and methods 
 Participating groups 
 A group of 15 laboratories was set up as an initiative 
within the European COST B35 action on  ‘ Lipid per-
oxidation associated disorders ’ . All the laboratories 
involved were experienced in the determination of 
lipid peroxidation and were blinded with regard to the 
identity of the samples.  Plasma samples 
 Residual fresh human plasma-EDTA samples of 
another study were pooled and divided into three 
batches of  ∼ 250 mL. Two of the batches were 
subjected to UVA irradiation at a dose of 15 or 20 
Joule using a UV chamber  ‘ Minitec ’ (Dr Groebel 
UV Elektronik GmbH, Ettlingen, Germany). The 
UVA irradiation source was a TL15W/05 lamp that 
emitted an energy spectrum in the UVA region 
(320 – 400 nm). The emitted dose was calculated 
using a UV-MAT dosimeter system. Each batch was 
divided into several petri dishes that were irradiated 
together in the UV chamber and then re-combined 
after treatment. The third batch was subjected to the 
same conditions without irradiation ( ‘ Control ’ ). The 
three fractions were then aliquoted in the required 
number and sample sizes for the 15 laboratories, 
with all aliquots in duplicate. 
 For the measurement of each lipid peroxidation 
analyte (or for each method where a laboratory used 
two methods) the laboratories received 15 encoded 
(blinded) samples randomly distributed consisting 
of  ‘ Control ’ ( n  5),  ‘ 15J ’ ( n  5) and  ‘ 20J ’ ( n  5). All 
samples were frozen and stored at   80 ° C and shipped 
on dry ice. Each laboratory received two batches of 
samples (batch 1 and batch 2) in order to test the 
day-to-day variation of the laboratories. The samples 
of batch 2 were only shipped after receiving the 
results of the fi rst batch in order to enforce separate 
analytical runs for the two batches. The overall plan 
of the study is illustrated in Figure 1. The samples 
were either stored at   70 ° C or were analysed within 
2 weeks (Table I). The analytes are stable at   80 ° C 
for at least 3 – 4 months, based on previous experience 
of the laboratories. 
 Lipid peroxidation markers 
 Lipid peroxidation was determined by the different 
laboratories using MDA ( n  8), F2-IsoPs ( n  3) 
and HNE ( n  5) as the studied markers. A variety 
of analytical techniques were employed, which are 
summarized in Table I together with important assay 
characteristics. 
 HPLC analysis of MDA-TBA adduct.  Five laboratories 
(D, E, G, I and L) determined MDA-TBA adducts 
according to Khoschsorur et al. [27] (laboratories D, 
G and L), Wong et al. [28] (laboratory E) and Londero 
and Greco [29] (laboratory I). Briefl y, plasma was 
mixed with 0.44 M phosphoric acid and 42 mM TBA, 
incubated in a water bath for 1 h, cooled and diluted 
1:1 with alkaline methanol. The supernatant was 
 separated by HPLC on RP C18 columns and fl uorimet-
ric detection was performed with excitation at 515 (G), 
525 – 527 (D, E) or 532 nm (I) and emission at 
550 – 553 nm (D, E, G, I), respectively. Laboratory L 
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 Figure 1. Scheme of sample treatment and distribution in the inter-laboratory validation study. 
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y.detected MDA-TBA adduct elution by UV/VIS 
detection at 533 nm. 1,1,3,3-tetra(m)ethoxypropane 
hydrolysed with 1% sulphuric acid was used as a 
 standard. 
 HPLC analysis of MDA-DNP adduct.  Two laboratories 
(C and F) determined MDA-DNP adducts according 
to Mateos et al. [30] (laboratory C) and Punchard and 
Kelly [31] (laboratory F). Briefl y, alkaline or acidic 
hydrolysis of protein bound MDA was achieved by 
incubating samples with NaOH (C) or HCl (F) in a 
60 ° C water bath for 30 – 40 min. The protein was pre-
cipitated with perchloric acid (C) or trichloroacetic acid 
(F) and removed by centrifugation. For derivatization, 
DNPH (5 mM in 2 M HCl) was added to the super-
natant and incubated for 20 min (C) or 60 min (F) at 
room temperature in the dark. MDA was analysed as 
its 2,4-dinitrophenylhydrazone derivative at 310 nm 
following separation by HPLC on RP C18 columns. 
1,1,3,3-tetraethoxypropane hydrolysed with 1% sul-
phuric acid was used as a standard. 
 Spectrophotometric analysis of MDA with 1-methyl-2-
phenylindole.  Laboratory A determined MDA accord-
ing to Gerard-Monnier et al. [32]. Briefl y, bound 
MDA was hydrolysed in the presence of butylated 
hydro xytoluene in acetonitrile, at pH 1 – 2 at 60 ° C 
for 80 min. A fi nal concentration of 10 mM 1-methyl-
2-phenylindole (in 3:1 acetonitrile/methanol) was 
added to each sample. After centrifugation the 
reaction was started by adding concentrated HCl (one volume of HCl to fi ve volumes of the reaction 
mixture). After 60 min incubation at 45 ° C, the 
absorbance of the supernatant was measured at 
586 nm. 1,1,3,3-tetramethoxypropane in the range 
0.25 – 4  μ M was used as a standard. 
 HNE-His ELISA.  The three laboratories H, J and L 
determined HNE-histidine conjugates based on previ-
ously described procedures [33]. Briefl y, samples were 
added to wells containing 25 mM (J, L)/100 mM (H) 
carbonate buffer pH 9.6 and incubated overnight in 
the fridge. The wells were washed with ddH 2 O (J, L) 
or 0.05% Tween 20 (H), before incubating at room 
temperature for 3 h with blocking solution (5% fat-free 
milk powder in ddH 2 O (J, L) or in 5% Tween 20 in 
PBS (H)). Subsequently they were washed again with 
water (J, L)/0.05% Tween 20 (H), before addition of 
anti-HNE-His antibody (H, 1/200; J and L, 1/100 dilu-
tion) and incubation for 2 h at room temperature. At 
the end of this time the wells were washed thoroughly 
with wash buffer (0.05% Tween-20 in PBS) followed 
by treatment with 0.1% sodium azide, 1.5% (J, L) or 
5% (H) H 2 O 2 in PBS for 30 min 
to inhibit sample peroxidase activity. After further 
extensive washing, secondary antibody (HRP-labelled 
Anti-Mouse IgG at 1/100 dilution (J, L) or 1/500 dilu-
tion (H) in PBS containing 1% BSA) was added and 
incubated for 1 h. After a few washing steps 
TMB was added. After 5 – 10 min (J) or 30 – 60 min (H) 
incubation, the reaction was stopped with H 2 SO 4 
and the plate was read at 450 nm. In parallel, a second 
 Table I. Overview of the used methods in the laboratories for determinations of malondialdehyde, F2-isoprostanes and 
4-hydroxy-2-nonenal. 
Analyte Laboratory Method Reference Storage Assay limits
MDA A Spectrophotometric with 
1-methyl-2-phenylindole 
(external standard)
[32]  – 80 ° C, 
 2 wks
LOD and LOQ   0.1  μ M
Linearity 0.25 – 4  μ M
C HPLC with DNPH (external 
standard)
[30]  – 80 ° C,
6 mth/2 wks
LOD 0.1  μ M, LOQ 0.3  μ M 
Linearity 0.3 – 20  μ M
D HPLC with TBA with 
fl uorescence detection 
(external standard)
[27]  – 20 ° C,
  2 wks
LOD 0.1  μ M, LOQ 0.2  μ M 
Linearity 0.2 – 6.4  μ M
E HPLC with TBA with 
fl uorescence detection 
(external standard)
[28]  – 80 ° C,
  2 wks
LOD 2 nM, LOQ 10 nM
Linearity 2 – 1000 nM
F HPLC with DNPH (internal 
standard)
[31]  – 80 ° C, 
 4 wks
LOD 0.1  μ M
Linearity 0.1 – 50  μ M
G HPLC with TBA with 
fl uorescence detection 
(external standard)
[27]  – 80 ° C,
3 – 4 mth/1 – 2 mth
LOQ 0.125  μ M
Linearity 0.25 – 8  μ M
I HPLC with TBA with 
fl uorescence detection 
(external standard)
[29]  – 80 ° C,
 ∼ 1 wk
LOD 5  μ M, LOQ 10  μ M
Linearity 10 – 1200  μ M
L HPLC with TBA with UV/
VIS detection (external 
standard)
[27]  – 80 ° C,
  1 mth/3 mth
LOD 0.14  μ M
Linearity 0.14 – 36  μ M
F2-isoprostanes B Commercial ELISA method 
(by OxisResearch)
 – 80 ° C, 
 6 wks/6 mth
LOD 2.7 pg/mL, LOQ 13.0 pg/mL 
Linearity 2 – 500 pg/mL
I LC-MS [36]  – 80 ° C,
 ∼ 1 wk
LOD 0.5 pg/mL, LOQ 1 pg/mL 
Linearity 1 – 1000 pg/mL
K GC-NICI-MS (internal 
standard)
[24,46]  – 70 o C,
3 mth/3 wks
LOQ 2.5 pg
Linearity 0.05 – 2.5 ng
HNE H (1) His-ELISA (external standard) [33]  – 40 ° C,
  2 wks
LOQ 0.2 nmol/ml
Linearity 0.25 – 10 nmol/mg BSA
H (2) HPLC with UV/VIS detection 
(external standard)
[34]  – 40 ° C, 
 2 wks
LOQ 250 pmol/ml (5 pmoles)
Linearity 0.2 – 12.5 nmol/mg BSA
I HPLC with fl uorescence 
detection (external standard)
[35]  – 80 ° C,
 ∼ 1 wk
LOD 5  μ M, LOQ 10  μ M
Linearity 10 – 5000  μ M
J His-ELISA (external standard) [33]  – 80 ° C, 
∼ 6 wks/3 wks
LOD 0.1 nmol/mg BSA,
Linearity 0.2 – 12.5 nmol/mg BSA
L His-ELISA [33,47]  – 80 ° C, 
 1 mth/3 mth
LOD 7 pmol/mg protein
Linearity 7 – 140 pmol/mg protein
  LPO measurement validation study  1207
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y.set of samples were run with PBS substituted for the 
primary antibody, to allow correction for non-specifi c 
binding. BSA treated with various amounts of HNE 
(either prepared in-house or purchased from Enzo Life 
Sciences, Exeter, UK) was used as a standard, in the 
range 0.1 – 12.5 nmol/mg protein. 
 HPLC analysis of free HNE.  Laboratory H determined 
free HNE as described previously [34]. Briefl y, 
plasma was mixed with BHT and desferrioxamine 
corresponding to  ∼ 1 mg protein/ml. The sample was 
then poured onto an Extrelut column and dichlo-
romethane was applied to collect the eluate in a fl ask 
containing 0.1 M acetate buffer. In order to obtain 
an aqueous phase dichloromethane was removed 
with a rotary evaporator not exceeding 20 ° C. The 
residual aqueous phase was applied to the ODS-
disposable pre-conditioned column and the residual 
sample was rinsed in a fl ask with methanol/water 
(15:85) and applied to the column. Free HNE was analysed at 223 nm. BSA treated with various 
amounts of HNE (prepared in house) was used as a 
standard, in the range 0.25 – 10 nmol/mg protein. 
 HPLC analysis of HNE-1,3-cyclohexandione adduct. 
 Laboratory I assayed HNE as a fl uorimetric derivative 
with 1,3-cyclohexandione separated by HPLC with 
fl uorometric detection with excitation at 380 nm and 
emission at 445 nm as described previously [35]. 
 Commercial ELISA for F2-isoprostanes.  8-epi-prosta-
glandin F 2 α  concentration in plasma samples was 
assayed by BIOXYTECH  ®  8-Isoprostane Assay Kit 
 Oxis Research ™ according to the manufacturer ’ s 
instructions following the extraction procedure. 
Briefl y, 50  μ L of plasma was extracted in 
chloroform:methanol (2:1 v/v) supplemented with 
50 mg/L butylated hydroxytoluene (BHT) and 500 
mg/L triphenylophosphine (TPP) cooled to 0 ° C. 
Following addition of MgCl 2 solution the organic 
1208  N. Breusing et al. 
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y.phase was collected and dried under argon. The lipid 
pellet was dissolved in methanol containing 50 mg/L 
BHT, alkalized with KOH solution and incubated at 
37 ° C for 30 min before acidifying to pH 3. The sam-
ple was cleaned fi rst on a C18 column by washes with 
1 mM HCl and heptane before eluting with ethyl 
acetate:heptane (1:1 v/v). After drying with anhydrous 
sodium sulphate, the liquid was transferred to a silica 
column and washed with ethyl acetate; bound mate-
rial was eluted with ethyl acetate:methanol (1:1 v/v) 
and dried under argon. The sample was dissolved in 
100  μ L of the DB buffer included in the assay kit. 
Competitive ELISA was performed exactly as in the 
assay manufacturer ’ s protocol. 
 F2-isoprostane analysis by GC-MS.  F 2 -IsoPs (esterifi ed 
and non-esterifi ed) were analysed according to 
Wiswedel et al. [24] and as described briefl y below. 
Esterifi ed lipids were hydrolysed in the presence of 
0.1 mM BHT as an antioxidant using KOH at 45 ° C. 
Thereafter, 9 α ,11 α -PGF 2 α  -d 4 was added as an inter-
nal standard. The samples were neutralized by addi-
tion of HCl to give pH  ∼ 2. The samples were extracted 
twice with ethyl acetate, the combined upper phases 
were evaporated under nitrogen and the residues were 
reconstituted in ethylacetate. The prostanoid extract 
was applied to NH 2 -cartridges equilibrated with 
n-hexane and then washed successively with n-hexane/
ethyl acetate (30/70, v/v), acetonitrile/water (90/10, 
v/v) and acetonitrile before elution with ethyl acetate/
methanol/acetic acid (10/85/5, v/v/v). Dried extracts 
were derivatized with pentafl uorobenzyl-bromide in 
the presence of  N,N -diisopropylethylamine, dried 
again before silylation with  bis -(trimethylsilyl) trif-
luoroacetamide (BSTFA). F 2 -IsoPs were separated 
and measured by GC(NICI)-MS (DSQ/Trace GC 
Ultra, Thermo Fisher Scientifi c, Dreieich, Germany) 
using a DB 5-MS column (J&W Scientifi c, Folsom, 
CA). Quantitative analysis was performed using 
selected ion monitoring of the carboxylate anion 
[M-181]  –  at  m/z 569 and  m/z 573 for F 2 -IsoPs and 
9 α ,11 α -PGF 2 α  -d 4 (internal standard; Cayman 
Chemicals Co., Ann Arbor, MI), respectively. The 
internal standard was quantifi ed using a 5-point cali-
bration curve. Each sample contained 0.5 ng of 8-iso-
PGF 2 α  and either 0.05 ng, 0.250 ng, 0.50 ng, 1.0 ng 
and 2.5 ng of 9 α ,11 α -PGF 2 α  -d 4 . 
 F2-isoprostane analysis by LC-MS.  8-iso-prostaglandin 
F 2 α  (8-isoPGF 2 α ) was assayed by LC-MS essentially 
using the method of Coolen et al. [36]. The fi rst step 
of sample preparation was alkaline hydrolysis. To 
extract the 8-iso-PGF 2 α  , the samples were purifi ed by 
using SEP-PAK C18 column containing octadecylsi-
lyl silica gel (Waters Associates, Milford, MA, USA). 
8-isoPGF2 α  was separated by HPLC and detected 
using electrospray ionization mass spectrometry. The 
separation was carried out on RP C18 with a linear gradient from 100% water adjusted to pH 5.7 with 
acetic acid to 100% acetonitrile. 8-isoPGF 2 α  in the 
range 1 – 1000 pg/mL was used as a standard. 
 Statistics 
 Data were analysed using Statistica (StatSoft, Tulsa, 
OK) and are represented as mean values with standard 
deviations. Using the results of the fi ve single measure-
ments in one laboratory, the intra-laboratory coeffi cient 
of variation (CVintra) was calculated as SD/mean  100 
for the three different treated sample types. Inter-labo-
ratory coeffi cient of variation (CVinter) was calculated 
for between-laboratory data from each measured param-
eter, independently to which method was used for the 
determination of the parameter. Signifi cance of differ-
ences between Control-, 15J- and 20J-treated samples 
was tested using the Student ’ s test for dependent sam-
ples considering  p   0.05 as signifi cantly different. Pear-
son ’ s correlation coeffi cients were calculated for 
relationships between batch 1 and 2 for the different 
markers. 
 Results 
 Of the 15 European laboratories participating in 
the inter-laboratory validation study, nine aimed 
to perform measurements on one parameter, four 
laboratories on two parameters and two on three 
parameters. Due to methodological problems four 
laboratories reduced their planned measurements by 
one parameter and one laboratory returned incom-
plete results. Finally, for the data analysis of the 
present work the complete data sets of 16 measure-
ments of 12 laboratories (named A to L) were avail-
able and used for data analyses. UVA-irradiation was 
used as the model system, because it represents a 
well-documented injury that is oxidative in nature 
[37]. 
 Intra-laboratory analysis 
 Intra-laboratory variation (CVintra) for the partici-
pating laboratories was calculated for each of the 
three treatments in both batches (control, 15J and 
20J) using the fi ve identical samples in each set. These 
CVintras represent the within-day-variation of each 
laboratory. As seen in Table II, CVintra for MDA 
determination showed a wide range between 1 – 175%. 
In batch 1, two of eight laboratories showed intra-
laboratory CVs of   10%, four of eight   20% and 
one of eight   30%. One laboratory was characterized 
by a CVintra of 110%. Intra-laboratory CVs in 
batch 2 were in general higher than in batch 1, where 
again two laboratories showed CVintras   10%. How-
ever, calculated intra-laboratory CVs were, except for 
two laboratories, comparable between the three sample 
  LPO measurement validation study  1209
 Table III. Intra-laboratory coeffi cients (CVintra) of F2-IsoP 
determinations in the single laboratories (B, I, K) in batch 1 and 2. 
Batch 1 Batch 2
C 15J 20J C 15J 20J
B  27.8% 57.1% 16.9% 18.7% 27.9% 32.8%
I  49.1% 44.4% 29.4% 45.1% 68.6% 56.4%
K 111.7% 39.0% 42.8% 32.2% 22.7%  5.6%
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y.types. The CVintra for F2-IsoPs and HNE also showed 
a wide range between 6 – 112% for F2-IsoPs and 
9 – 136% for HNE (Tables III and IV). In contrast to 
MDA, CVintra of these parameters were characterized 
by greater differences between the two batches and less 
consistent CVs within the individual laboratories. 
 In order to study the day-to-day variation in the 
laboratories, correlation coeffi cients between batch 
1 and batch 2 were calculated for all three lipid 
peroxidation parameters. Correlation analysis indi-
cated a strong statistically signifi cant positive cor-
relation between results of batch 1 and batch 2 for 
MDA ( r  0.82) and F2-IsoPs ( r  0.93), as shown 
in Figure 2; there was also a weak but signifi cant 
correlation for HNE ( r  0.62). 
 In an additional experiment, one laboratory (labo-
ratory L) performed the determination of MDA and 
HNE in the same 15 samples. Figure 3 shows the 
measured MDA and HNE results in ascending 
order within each treatment set. Interestingly, for 
MDA the fi ve lowest concentrations were found in 
the control samples as expected. There was a tendency 
for the values to increase with increasing irradiation, 
although the distinction between the 15J and 20J sets 
is not clear. The values for HNE generally showed a 
similar pattern within each treatment set, although 
the values were slightly more variable. In particular, 
there was no clear trend to higher values with increased 
severity of treatment, demonstrating a low specifi city 
of this HNE method for detecting oxidative damage 
to lipids in plasma. It should be noted that the values 
of the MDA and HNE cannot be directly compared, 
as the HNE analyses are expressed as nanomols of 
HNE per mg of protein (i.e. the extent of protein 
modifi cation within the sample), rather than as an 
absolute concentration for HNE. 
 Inter-laboratory analysis 
 Mean, SD, median and CVinter of MDA, F2-IsoPs 
and HNE measurements are presented in Table V. The 
inter-laboratory coeffi cient of variation for all three 
markers was calculated to be very high and ranged from 
63 – 190% (Table V), with the inter-laboratory CVs of  Table II. Intra-laboratory coeffi cients (CVintra) of MDA deter-
minations in the single laboratories (A – L) in batch 1 and 2. 
Batch 1 Batch 2
C 15J 20J C 15J 20J
A 10.8% 18.9% 12.5% 45.8% 33.6% 29.3%
C 11.3% 29.6% 23.0% 27.7% 25.4% 12.8%
D 1.2% 1.8% 3.4% 10.7% 6.6% 2.7%
E 11.1% 7.5% 7.7% 22.5% 12.2% 33.8%
F 112.1% 110.2% 135.3% 151.7% 46.0% 49.6%
G 10.9% 13.4% 11.8% 10.1% 8.3% 4.5%
I 6.6% 11.7% 12.3% 17.9% 23.0% 22.6%
L 6.1% 9.9% 3.4% 6.9% 1.7% 2.0%HNE detection being highest and of MDA detection 
lowest. A comparison of the data for all three lipid 
peroxidation analytes and all treatments between 
batch 1 and batch 2 showed that the means and medi-
ans were in almost all cases lower in batch 2, by as 
much as 5-fold for some sets of data. Due to the high 
inter-laboratory variation, a statistically signifi cant 
increase of lipid peroxidation could not be found in 
the oxidized samples, neither in batch 1 nor in batch 
2 (Table V,  p  0.05). 
 The mean values of each laboratory for MDA 
 ‘ control ’ samples of batch 1 are presented in Figure 4 
in ascending order with the median value of 1.11 
 μ mol/L indicated. A factor of 49 separates the high-
est and lowest values. Only two of the eight labora-
tories were within   50% of the median of MDA 
control samples, whereas four laboratories were 
within   50% of the median observed in both UVA-
treated samples (data not shown), demonstrating 
that the variation of the results might be affected 
by the state of oxidation. Interestingly, the highest 
values for MDA were determined in laboratories 
using a method other than TBA-adduct detection by 
HPLC (Figure 4). The median for MDA detection 
by HPLC was calculated to be 0.55  μ mol/L for MDA 
control samples. It was also observed that the mean 
values of ELISA-based HNE-His detection ( n  3) 
were up to 20-fold higher than mean values for chro-
matographic methods ( n  2; Table VI). 
 Potential for detection of UVA-induced 
lipid peroxidation 
 An important aspect of the study was to test whether 
the levels of lipid peroxidation products assayed 
were able to distinguish and predict correctly the 
induced lipid peroxidation, according to the severity  Table IV. Intra-laboratory coeffi cients (CVintra) of HNE deter-
minations in the single laboratories (H, I, J, L) in batch 1 and 2. 
Batch 1 Batch 2
C 15J 20J C 15J 20J
H 26.7% 38.9% 33.2% 82.2% 31.0% 50.9%
J 91.3% 69.0% 69.0% 14.4% 49.6% 135.8%
L 15.4% 16.9% 10.9% 94.4% 35.8% 22.1%
H 55.5% 26.9% 22.2% 14.7% 33.9% 32.6%
I 58.9% 57.9% 40.4% 9.4% 12.2% 9.9%
1210  N. Breusing et al. 
 Figure 2. Results of correlation analyses between batch 1 and batch 2 for MDA, F2-isoprostanes and HNE determination. Correlation 
coeffi cients and  p -values are presented. 
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y.of the irradiation dose. With regard to MDA deter-
mination, fi ve out of eight laboratories showed a 
signifi cant and progressive increase in MDA in 15J 
and 20J-treated samples (Figure 5A). These results 
are in contrast to those of F2-isoprostane and HNE 
determinations, in which there are only partial 
signifi cant differences or no signifi cant differences 
(Figures 5B and C). It was further shown that the 
simultaneous determination of HNE-His by ELISA 
(H-1 in Figure 5C) and HPLC (H-2 in Figure 5C) 
in one laboratory (H) resulted in different HNE 
concentrations (18-fold for  ‘ 20J ’ samples). 
 Further analyses tested whether differences in 
lipid peroxidation can also be observed if data of 
all laboratories were used, and the result is shown 
in Figure 6. There was no statistically signifi cant 
rise in MDA, F2-IsoPs and HNE when the data of 
all laboratories were analysed together. However, 
the observed changes of HNE were characterized 
by a very high variation ( ∼ 3-fold mean value). 
 Discussion 
 Besides the quantifi cation of inter-laboratory variations 
in the determination of lipid peroxidation markers, we  Figure 3. Results of an intra-laboratory comparison of two methods fo
detection by ELISA. Measurements were carried out on 15 samples in 
15J, 20J). Results of MDA and HNE analysis were both arranged in or
the sample sets for the two analytes are separate (10 separate equivalenwere interested to assess the contribution of intra-
laboratory variation to inter-laboratory variation. Our 
data for MDA measurements indicate low within-day 
variances characterized by intra-laboratory CVs 
between 1 – 30% in most of the laboratories. There was 
one laboratory that had serious diffi culties in yielding 
similar and reproducible results, highlighted by the 
fact that intra-laboratory CVs for the different sample 
types ranged between 110 – 175%; the method used in 
this case was the DNPH-HPLC analysis of MDA. 
Within-day variances for HNE and F2-IsoP were 
characterized by higher within-day variances and less 
consistency within the single laboratories compared 
to MDA measurements. 
 To investigate if the laboratories are able to repro-
duce their results, identical samples were analysed for 
second time coded to the laboratories as batch 2 rep-
resenting the day-to-day variance of the laboratories. 
We observed a good correlation between the results 
observed in batch 1 and 2, with correlation coeffi -
cients of 0.82 for MDA and 0.93 for F2-IsoP. A sta-
tistically signifi cant but only weak correlation was 
found for HNE. The samples of the second batch 
were older at the time of measurement than samples 
of batch 1 (as all the samples were derived from one r lipid peroxidation: MDA detection with TBA-HPLC and HNE 
total for each analyte, fi ve for each of the three treatments (control, 
der of increasing values found within each treatment set; note that 
t aliquots per treatment). 
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 Table V. Mean, standard deviation (SD), median and inter-laboratory coeffi cient of variation in two independent (batch 1 and 2) 
measurements of Malondialdehyde ( n  8), F2-isoprostanes ( n  3) and 4-Hydroxy-2-nonenal ( n  5). 
Batch 1 Batch 2
Mean SD Median CVinter (%) Mean SD Median CVinter (%)
MDA ( μ mol/l)  n  8 C 1.35 1.13
1.05
1.10
498.6
829.7
1278.4
0.009
0.121
0.156
1.11
1.52
1.28
693.8
552.8
1075.0
0.018
0.015
0.016
 83.7 1.06
1.28
1.25
303.5
580.0
727.5
0.081
0.091
0.065
1.41
1.76
1.26
267.9
735.6
1000.6
0.105
0.116
0.109
0.41
0.71
0.85
290.8
72.4
260.7
0.015
0.013
0.015
133.5
15J 1.50
1.60
584.1
889.1
1257.7
0.015
0.067
0.082
 70.1 138.1
20J  68.6 100.4
F2-IsoP (pg/ml)  n  3 C  85.4  88.3
15J  93.3 126.8
20J 101.6 137.5
HNE (nmol/mg)  n  5 C  63.6 130.2
15J 180.5 127.4
20J 189.9 168.1
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y.original plasma pool), which raises the possibility of 
either an increase in lipid peroxidation due to longer 
storage and a decrease due to degradation processes. 
As the absolute values (median) of all markers in 
samples of the second batch are slightly lower com-
pared to those of batch 1 and there was increased 
variability, the occurrence of degradation processes 
seems most likely. 
 Malondialdehyde, 4-Hydroxy-2-nonenal and 
F2-Isoprostanes have been extensively used during 
recent years as markers of lipid peroxidation. 
However, different analytical methods established for 
each of these parameters generate the problem of 
inconsistent results, either due to method specifi city 
or sensitivity. Furthermore, oxidative stress markers 
are by nature easily prone to over-estimation if strin-
gent precautions are not taken in sample handling 
and storage. For example, high temperature and 
low pH during the reaction of MDA with TBA may 
cause artefactual formation of lipid peroxidation 
products. Consequently, some of what is measured in 
the fi eld of lipid peroxidation studies may in fact be 
artifact. Thus, quantifi cation of lipid peroxidation  Figure 4. Results of MDA determination of control samples of 
eight laboratories, arranged in order of increasing values found. 
HPLC with TBA-adduct detection was employed except where 
otherwise stated; two laboratories used HPLC with DNP-adduct 
detection and one laboratory used 1-methyl-2-phenylindole 
colourimetric detection.  n  5 for all sets. can be misleading and the range might further be 
increased by an expected high variance between labo-
ratories and analytical methods. Since there is a lack 
of knowledge in the literature about the variation in 
the measurement of lipid peroxidation markers, espe-
cially between laboratories, the aim of the present 
validation study was to quantify intra- and inter-
laboratory variation in the determination of lipid 
peroxidation. Varied protocols in the participating 
laboratories for analysis of each lipid peroxidation 
compound were intentionally allowed, in order to 
mimic the real situation in oxidative stress research. 
 As expected, the reported values for the lipid 
peroxidation markers measured in this group of 
COST B35 laboratories were characterized by a high 
variability between laboratories, illustrated by the 
fact that inter-laboratory CVs were up to 190%. Thus, 
it appears that there was very limited agreement of 
the different methods in terms of detection of each 
parameter. Interestingly, MDA determinations in 
eight laboratories performed by both different HPLC 
methods and one colourimetric method showed the 
lowest inter-laboratory variations. This fi ts with the 
observation that, in general, recent measurement of 
MDA in human plasma of healthy volunteers using 
TBA falls into a relatively narrow concentration range 
 ∼ 1 – 5  μ mol/L [38 – 42], although in some cases lower 
values have been reported [43]. Interestingly, the 
highest values for MDA were found using 1-methyl-
2-phenylindole as the reagent, probably because this 
method involves an acid hydrolysis step that releases 
protein-bound MDA, a signifi cant form of MDA in 
plasma [32]. Likewise, chromatographic separation  Table VI. Comparison of the mean values for determination of 
4-Hydroxy-2-nonenal by ELISA ( n  3) and HPLC ( n  2). 
Batch 1 Batch 2
HPLC 
(nmol/mg)
ELISA 
(nmol/mg)
HPLC 
(nmol/mg)
ELISA 
(nmol/mg)
C 0.012 0.016 0.008 0.130
15J 0.012 0.103 0.007 0.148
20J 0.010 0.130 0.008 0.103
1212  N. Breusing et al. 
 Figure 5. Results of the determination of MDA ( n  8), F2-isoprostanes ( n  3) and HNE ( n  5) in the laboratories participating in the 
validation study. The laboratories are identifi ed A – L. One laboratory (H) measured HNE both by ELISA (H-1) and HPLC (H-2). Values 
are means of batch 1.  1 p   0.05: C vs 15J  C vs 20J  15J vs 20J;  2 p   0.05: C vs 15J  C vs 20J;  3 p   0.05: C vs 20J;  4 p   0.05: C vs 
20J  15J vs 20J. 
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y. with UV detection of the MDA-DNP adduct, which 
also measures both free and protein-bound MDA, 
resulted in absolute concentrations of MDA 2 – 4.5-
fold higher than the median of the chromatographic 
detection with TBA. In fact, the four laboratories (D, 
E, G, I) that carried out MDA analysis by TBA-
HPLC gave the most closely matching profi les, 
although the absolute values still showed considerable 
variation. These fi ndings support the theory that the 
use of different methods contributes to the broad 
range reported here.  Figure 6. Results of relative changes of MDA, F2-isoprostanes and 
HNE in control (C) samples and samples treated with 15J and 20J 
UVA. Bars demonstrate the results of eight (MDA), three (F2-
isoprostanes) and fi ve (HNE) laboratories, respectively. The control 
was set to 100%. Note the log scale.  In our group of laboratories, HNE and F2-IsoP 
determinations were conducted by two and three 
methods, respectively, and particularly the high varia-
tions in HNE values between the fi ve involved labo-
ratories suggests serious problems, either in the 
analytical methods or in sample handling. However, 
sample handling and method variation probably 
contributes to the variability for MDA also, although 
this method seems to be more robust. Since it was 
reported by the laboratories performing HNE-ELISA 
that the concentrations analysed bordered on the 
detection threshold of the method and were in the 
range of the two lowest standards, it appears that 
the present method is not yet optimal for the analysis 
of HNE-protein adducts in EDTA-plasma exposed to 
UVA, possibly because the extent of peroxidation 
obtained after UVA treatment was low. The HNE-His 
ELISA used was developed for analysis of cultured 
cells and cell lysates and has not yet been adapted 
specifi cally for HNE-His determinations in the human 
plasma samples. This study represents the fi rst time 
that the HNE-His ELISA has been tested in oxidized 
plasma; previously only HNE spiking of EDTA-
plasma was tested and found to give 90% recovery. 
The methods used for F2-isoprostanes all involved an 
alkaline hydrolysis step and therefore measured both 
free and phospholipid-esterifi ed isoprostanes in the 
plasma. However, in GC-NICI-MS the analysis is 
based on one gas chromatographic peak that contains 
4 regioisomers, whereas in LC-MS the regioisomers 
can be separated and 8-iso-PGF2 α quantifi ed; the 
ELISA method similarly detects only 8-iso-PGF2 α . 
This in part explains the higher values from the 
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y.GC-NICI-MS analysis (laboratory K), although it 
was noted that the values measured for the control 
samples were substantially higher than the range of 
200 – 300 pg/mL normally measured by that labora-
tory [24] and reported in other studies [21 – 23,44]. 
Sircar and Subbaiah [45] also reported that 
F2-isoPs measured by LC-MS were lower than those 
measured by GC-MS(MS). A previous study using 
an immunoassay for 8-iso-PGF2 α (15-F2t-isoP) 
reported values in human plasma in the region of 
250 – 350 pg/mL, i.e. lower than those measured in 
the present study. Thus, again it can be seen that the 
methodology can change considerably the values of 
lipid peroxidation products measured. 
 An important goal of the present study was to test 
the ability of both the laboratories and analytical 
methods to discriminate samples with different MDA 
concentrations induced by an irradiation with UVA 
at different doses. We observed good correlations 
between predicted lipid peroxidation and measured 
MDA concentrations for most of the laboratories. 
Although F2-IsoP and HNE are also well established 
parameters of oxidative stress, most of the partici-
pating laboratories did not reveal abundant lipid 
peroxidation in moderately UVA-irradiated samples 
using MS for F2-IsoPs and HNE-His ELISA or 
HPLC for HNE. It might be possible that the num-
ber of participating laboratories measuring these ana-
lytes was too small and that the levels of F2-IsoP and 
HNE generated by UVA in EDTA-plasma samples 
used were too low. The fact that the GC-MS method 
for F2-IsoPs measures several F2-IsoPs both from 
esterifi ed and free F2-IsoPs, whereas the ELISA 
method detects only 8-iso-PGF2 α  probably contrib-
uted to the variability observed. 
 In the past the European Standards Committee on 
Oxidative DNA Damage [16] was set up to explore 
the reasons for discrepancies in the measurement of 
oxidative DNA damage and they were able to make 
several practical recommendations to reduce oxida-
tion artefacts during DNA isolation. Thus, it appears 
advisable that a comparable board should be set up 
in order to resolve the problems associated with high 
inter-laboratory variability in lipid peroxidation assays 
and resulting from the use of different analytical 
methods for each analyte. 
 An important conclusion from this validation 
study is that malondialdehyde, F2-isoprostanes and, 
to a lesser extent, 4-Hydroxy-2-nonenal serve as 
reliable indicators of lipid peroxidation in human 
EDTA-plasma samples treated by UVA. Although 
the inter-laboratory variations were found to be high, 
the intra-laboratory variations showed an accept-
able range. The measurement of MDA by HPLC 
has emerged as one of the most reliable approaches 
to assess lipid peroxidation status, because MDA 
detection was characterized by both the lowest inter-
method and inter-laboratory variations and, importantly,  LPO measurement validation study  1213
the potential to refl ect the lipid peroxidation status in 
human EDTA-plasma samples subjected to different 
doses of UVA-irradiation. However, it is also neces-
sary to note that the conclusions from this study  in 
vitro cannot necessarily be extrapolated to the analy-
sis of free radical-induced damage  in vivo . 
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